$SRPT set to release preliminary data readout for sirNA DM1 and FSHD programs tomorrow, following strong performance today.

Today’s most trending tickers with positive sentiment (last 24h):

$UGRO: 33
$SPY: 22
$TSLA: 12
$ASTS: 10
$IPO: 10
$ORBS: 10
$RKLB: 9
$ARM: 9
$SRPT: 8
$META: 8
$MU: 7
$USEG: 7
$HOOD: 7
$GLD: 7
$SPCE: 6
$WKEY: 6
$NVDA: 5
$AAOI: 5

Original post on benzinga.com

Crude Oil Moves Lower; Cintas Raises FY2026 Forecast The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forec...

#ARM #AVXL #BRZE #CTAS #Equities #MAZE #Mid-Afternoon #Market […]

[Original post on benzinga.com]

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Sarepta (NASDAQ:SRPT) reported first clinical data from Phase 1/2 studies of two αvβ6 integrin-targeted siRNA candidates, SRP-1001 (FSHD1) and SRP-1003 (DM1).Early results show dose-dependent muscle and plasma exposures, single-dose target knockdown, and favorable tolerability with no dose-limiting toxicities reported to date. An investor webcast is scheduled March 25, 2026.

#SRPT Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

www.stocktitan.net/news/SRPT/sarepta-announ...

Sarepta to reveal first human data for two rare muscle disease drugs At 8:30 a.m. ET on March 25, Sarepta will present early Phase 1/2 results for SRP-1001 and SRP-1003, marking a first clinical look at its siRNA pipeline.

#SRPT Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

www.stocktitan.net/news/SRPT/sarepta-to-sha...

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® Sarepta (NASDAQ:SRPT) will submit supplemental NDAs by the end of April 2026 seeking conversion of AMONDYS 45 and VYONDYS 53 accelerated approvals to traditional approvals.ESSENCE topline showed non‑significant primary results (LSM difference 0.06 steps/sec, P=0.309); an updated COVID‑adjusted analysis reached P=0.050. No new safety signals; company will include ESSENCE and real‑world evidence in the sNDAs.

#SRPT Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

www.stocktitan.net/news/SRPT/sarepta-provid...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RDW, #LPTH, #SRPT, #KEP, #NVTS

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FDX, #SRPT, #GCO, #UDMY, #CF

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FDX 49.0x
2. #SRPT 9.8x
3. #UNH 9.7x
4. #MRVL 6.4x
5. #GCO 5.8x

#OptionFlow #OptionsTrading #Trading

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program Sarepta Therapeutics (NASDAQ:SRPT) opened applications for Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Scholarships of up to $5,000 will be awarded to up to 20 individuals with Duchenne and up to 5 siblings.Applications are accepted through May 15, 2026; recipients will be notified before July 31, 2026 and awards distributed to schools for fall 2026 enrollment.

#SRPT Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

www.stocktitan.net/news/SRPT/sarepta-therap...

#Earnings to watch Wed, Feb 25th, 2026 #APG #AVA #BMO #COMM #CRCL #DOLE #HNI #HOV #HUT #LOW #PLAB #TJX #A #ADTN #AI #ARRY #CRM #HEI #IONQ #NTNX #NVDA #PSKY #PSTG #SARO #SBLK #SNOW #SNPS #SRPT #STN #TASK #TCOM #TTD #UHS #URBN #VAC #ZM

#SRPT continues to rise, validating gene therapy and triggering milestones & royalties

Today’s most trending tickers with positive sentiment (last 24h):

#OPEN: 16
#SPY: 16
#MSFT: 11
#TSLA: 9
#ASTS: 9
#TLT: 9
#AMZN: 8
#ASTI: 6
#QQQ: 5
#OLOX: 4
#SGN: 4
#GLD: 4
#BBAI: 4
#EVER: 4
#AAPL: 4
#SPX: 4
#SRPT: 4
#VOO: 4

#SRPT continues to trend upward, steady accumulation precedes earnings release.

Today’s most trending tickers with positive sentiment (last 24h):

#OPEN: 34
#SPY: 19
#NVDA: 15
#AMZN: 14
#TSLA: 11
#TLT: 10
#ASTS: 9
#SPX: 9
#MSFT: 8
#QQQ: 6
#ASTI: 6
#WMT: 6
#SRPT: 6
#CVNA: 6
#OLB: 5
#DE: 5
#DFNS: 5
#RXT: 5

#SRPT to present Phase 3 EMBARK study data on Monday, potentially driving stock movement.

📢 Stocks Trending NOW: #CRWV #USAR #BNAI #BATL #GXAI #MP #IONQ #SKYT #SRPT #EVTV

Today’s most trending tickers with positive sentiment (last 24h):

#USAR: 23
#BTC: 9
#NVDA: 9
#GOLD: 8
#ARBE: 7
#SRPT: 7
#MU: 7
#SPY: 6
#ETH: 5
#SLV: 5
#IREN: 5
#MSFT: 5
#RDW: 4
#TALK: 4
#AAPL: 4
#QQQ: 4
#GOOG: 4
#SVRE: 4

Today’s most trending tickers with positive sentiment (last 24h):

#NVDA: 17
#BNAI: 13
#SRPT: 12
#SPY: 10
#TSLA: 9
#USAR: 9
#MU: 7
#AAPL: 7
#MSFT: 6
#WHLR: 5
#TALK: 5
#GME: 5
#META: 5
#NXXT: 4
#SLV: 4
#MIGI: 4
#BTC: 4
#ZSL: 4

I believe #SRPT will deliver a big surprise in 2026 when the efficacy data for Elevidys in treating Duchenne muscular dystrophy (DMD) is released.

#SRPT's market cap considered low for potential Roche buyout, remains top trending stock on Stocktwits and presents at J.P. Morgan Healthcare Conference.

Today’s most trending tickers with positive sentiment (last 24h):

#SPY: 18
#BABA: 18
#GNPX: 13
#EVTV: 13
#META: 12
#LITM: 11
#GOOGL: 10
#RIME: 10
#ATON: 10
#IREN: 10
#INUV: 9
#JP: 9
#NVDA: 9
#TSLA: 9
#JPM: 8
#AMZN: 8
#ORCL: 8
#SRPT: 8

#SRPT Stock CRASHING – Why Sarepta Therapeutics Is Down 11% Today (Regulatory & Revenue Fears)
youtu.be/_qYaQbl30O0

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues Sarepta (NASDAQ:SRPT) reported preliminary, unaudited Q4 2025 net product revenue of $369.6M and full-year 2025 net product revenue of $1.86B. ELEVIDYS revenue was $110.4M in Q4 and $898.7M for 2025; PMO revenues were $259.2M in Q4 and $965.6M for 2025. Preliminary cash, cash equivalents, restricted cash and investments totaled approximately $953.8M at Dec 31, 2025. The company reconfirmed a yearly ELEVIDYS sales floor of $500.0M but will not provide detailed 2026 guidance until initiatives are evaluated. Results are preliminary and subject to adjustment; final 2025 results expected in late February 2026.

#SRPT Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

www.stocktitan.net/news/SRPT/sarepta-report...

#SRPT set to move at JP Morgan Health conference with potential catalysts for short squeeze

Today’s most trending tickers with positive sentiment (last 24h):

#SNDK: 12
#GNPX: 10
#TSLA: 9
#OPEN: 9
#WMT: 8
#SPY: 8
#INTC: 8
#MU: 7
#ASTI: 6
#QQQ: 6
#ASTS: 5
#BTC: 5
#IWM: 5
#EOSE: 5
#NVDA: 5
#SP500: 5
#SRPT: 4
#BE: 4

#SRPT poised for significant growth and short squeeze potential ahead of JP Morgan Health conference.

#SRPT poised for significant growth and potentially reaching $50 soon, following its clinical trial application for SRP-1005 targeting Huntington's disease.

Most Searched, Thursday December 18, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Dec 18th - #ATHA #RZLV #WRD #TWO #TLRY #SRPT #SOC #RAMP #PTEN #ONDS #$OBE #MGNX #IQ #FCEL #FBYD #DAWN #DAVE #CAAS #ALLO #AESI - More: crystalequityresearch.com/most-searche... - #smallcap

Assessing Sarepta Therapeutics (SRPT) Valuation After a Recent Share Price Rebound Why Sarepta Therapeutics Stock Is Back on Investors Radar Sarepta Therapeutics (SRPT) has quietly bounced over the past month, even after a tough year where the stock is still down sharply. That disco...

Assessing #Sarepta Therapeutics, #SRPT, Valuation After a Recent Share Price Rebound

simplywall.st/stocks/us/ph...